LYEL DCF Valuation - Lyell Immunopharma Inc

Watchlist Manager

Watchlist

Price: 22.39 USD -6.12% Market Closed

Market Cap: $521.9m

	Lyell Immunopharma Inc NASDAQ:LYEL	US
T	Tong Hua Holding PCL SET:TH	TH
	Avalon Advanced Materials Inc TSX:AVL	CA
	Shiny Chemical Industrial Co Ltd TWSE:1773	TW
	Australian Vintage Ltd ASX:AVG	AU
	Lion Metal Works Tbk PT IDX:LION	ID
	Surya Permata Andalan Tbk PT IDX:NATO	ID
	Napier Port Holdings Ltd NZX:NPH	NZ
	Hebei Changshan Biochemical Pharmaceutical Co Ltd SZSE:300255	CN
	Global Cannabis Applications Corp OTC:FUAPF	CA
L	Lepu Scientech Medical Technology Shanghai Co Ltd HKEX:2291	CN
	Hutchison Telecommunications Hong Kong Holdings Ltd HKEX:215	HK
	Bank7 Corp NASDAQ:BSVN	US
N	NanoString Technologies Inc OTC:NSTGQ	US
	Nitori Holdings Co Ltd OTC:NCLTF	JP
H	Hanjin Heavy Ind & Const Holdings Co Ltd KRX:003480	KR
	Amarjothi Spinning Mills Ltd BSE:521097	IN
	Redwoods Acquisition Corp NASDAQ:WENA	US
I	I Power Solutions India Ltd BSE:512405	IN
K	K2 F&B Holdings Ltd HKEX:2108	SG

LYEL's DCF value cannot be reliably calculated.

Relative Valuation Wall Street Price Targets

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.